Tilray Brands, Inc. is set to announce its financial results for the fourth quarter and full fiscal year ended May 31, 2026, after the financial markets close on Tuesday, July 28, 2026. The announcement will provide insights into the performance of the global lifestyle and consumer packaged goods company across its cannabis, beverage, and wellness segments.

Following the release, Tilray will host a live conference call and audio webcast at 4:30 PM Eastern Time on July 28, 2026. The webcast will be accessible on the Events & Presentations section of Tilray’s Investor Relations website, allowing stakeholders to listen to management’s discussion of the results.

Tilray Brands, Inc. operates as a leading global lifestyle company with a presence in Canada, the United States, Europe, Australia, and Latin America. The company’s portfolio includes over 40 brands across more than 20 countries, spanning cannabis offerings, hemp-based foods, and craft beverages.

The upcoming financial disclosure will cover the performance metrics for the fourth quarter and the full fiscal year. Investors and analysts will focus on revenue trends, profitability, and strategic developments across Tilray’s diverse business verticals.

For access to the conference call and webcast, stakeholders can visit the designated section on Tilray’s Investor Relations website. The company remains a transformative force in the cannabis, beverage, and wellness industries, aiming to elevate lives through moments of connection.

Tilray Medical, a division of Tilray Brands, Inc. (NASDAQ: TLRY, TSX: TLRY), announced the commercial launch of its first medical cannabis product in Panama on July 09, 2026. This strategic move marks a significant milestone in the company’s global expansion, aiming to improve patient access to pharmaceutical-grade cannabinoid medicines in Latin America. The launch involves Tilray Oral Solution CBD100, distributed through Farmacias Arrocha, one of Panama’s leading pharmacy networks.

The product shipment originated from Tilray Medical’s EU-GMP-certified production facilities in Portugal, conducted through a joint venture with Solana Life Group S. de R.L. Patients can access Tilray Oral Solution CBD 100 under medical prescription, providing regulated, pharmaceutical-quality medical cannabis through established healthcare channels. The launch aligns with Panama’s medical cannabis framework established under Law 242 of 2021 and follows Resolution No. 0406 of May 12, 2026, issued by the Ministry of Health.

Rajnish Ohri, President, International, Tilray Brands, stated that the launch reflects the company's vision to expand access to cannabinoid-based medicines through trusted healthcare systems. He emphasized the commitment to working alongside healthcare providers, regulators, and patients to advance medical education and deliver high-quality treatment options.

Tilray Medical serves patients across more than 20 countries, including Europe, Australia, Canada, and Latin America. The company’s facilities in Portugal serve as a strategic global export hub, supplying EU-GMP-certified medical cannabis products to regulated markets. The Panama launch represents another step in Tilray Medical’s broader strategy to expand access across Latin America, an emerging region for medical cannabis.

The Ministry of Health recently introduced the Medical Cannabis Users and Authorized Caregivers Identification System (SIUCMAA), creating a structured pathway for physician authorization and patient registration. Tilray Oral Solution CBD100 is intended for use in patients with qualifying medical conditions authorized under Panamanian legislation, adhering to rigorous European Union Good Manufacturing Practice (EU-GMP) standards.

Key Details of the Launch

Tilray Medical remains focused on advancing patient care, supporting clinical education, and investing in research to address unmet patient needs worldwide. The company continues to leverage its platform to support growing international demand while maintaining high pharmaceutical manufacturing standards.